Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

For the first time in UK, a wider audience can get first-hand experience of the NeoNavia® micropulse biopsy system for breast cancer

During the annual meeting of the British Society of Breast Radiology (BSBR) on 3-5th November in Bristol, radiologists get to gain first-hand experience using the innovative micropulse technology in meat models via a series of hands-on workshops arranged by NeoDynamicsHigh interest in the workshops has led to additional sessions being added and over 50 radiologists being able to try the new system. The BSBR workshops represent a milestone for NeoDynamics and for the first time a wider audience will get to not only hear about the NeoNavia system but try it for themselves. "With the UK

Nomination committee appointed ahead of 2020 Annual General Meeting of Pricer AB

Pricer AB (publ) has appointed the nomination committee ahead of the 2020 Annual General Meeting. In accordance with the decision at the Annual General Meeting on April 25, 2019 Pricer’s Chairman of the Board Bernt Ingman has contacted the company’s largest shareholders to form a Nomination Committee. The Chairman has, when selecting the largest shareholders, given due consideration to groups of shareholders who have indicated a wish to participate jointly in the Nomination Committee. The shareholders and representatives comprising the Nomination Committee, in addition to the Chairman

Modern classics, retro sport and colour explosions in this spring’s Limited Edition

This March, KappAhl launches its much-anticipated new Limited Edition collection. Bold, timeless, and strongly influenced by retro sport styles, the collection embraces spring’s colours, creating an updated wardrobe with new silhouettes and details.-    “This spring’s Limited Edition will hit stores just as we are starting to dream of the perfect spring wardrobe. The collection is influenced by retro sport styles, combined with a more preppy look. We have challenged the classic base of the collection with new volumes and peppy colours, to create a wonderfully fresh spring look,” says

UPM closes paper machine 2 in Rauma – Employee consultation processes concluded

(UPM, Helsinki, 5 November 2019 at 10:00 EET) – In early September UPM announced plans to permanently close paper machine 2 in Rauma, Finland. The employee consultation processes have now been completed. Paper machine 2 in Rauma will be permanently closed on 6 November 2019. The reduction of personnel is 179 (159 permanent and 20 temporary contracts not prolonged). Following the closure, SC paper production capacity will be reduced by 265.000 tonnes annually. The production on the remaining two paper machines in Rauma will continue as before. “The recent weeks have not been easy for

Klaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platform

Important InformationIn the information below, “this press release” refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an

Klaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platform

Klaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platformKlaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platform

ASSMANN Büromöbel opens a showroom in Manchester

Having acquired segments of Frem Group Screens Ltd. last year, the German furniture manufacturer continues to build on its presence in the United KingdomWith successful showrooms already in operation in London and Glasgow, ASSMANN Büromöbel GmbH & Co. KG officially opened the doors to its new ASSMANN showroom in Manchester in mid-October. More than 100 visitors celebrated with the German mid-sized company, which is one of the UK's best-performing office furniture manufacturers. "With the new showroom in Manchester, we will have an even greater presence in the UK market!", managing partner

Midsona publishes prospectus relating to the rights issue

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. ADDITIONAL RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.The prospectus, relating to the rights issue in Midsona AB (publ) (“Midsona”) of approximately SEK 600 million after issue costs, has

Limited liability companies and co-operatives must submit financial statements to the Finnish Trade Register; even active businesses may risk deregistration

The Finnish Patent and Registration Office (PRH) will this week send reminder letters to about 5.000 limited liability companies and co-operatives that have not submitted their financial statements for registration within one year from the end of the financial period. The PRH can deregister even an active limited liability company or co-operative if they do not file the financial statements by the date given on the letter.Deregistration means that the business is out of action. All limited liability companies and co-operatives must file their financial statements with the Trade Register

Interim report January - September 2019

A quarter of recordsThird quarter July - September 2019 · Net sales amounted to 282.7 MSEK (232.2), which is an increase by 21.7 percent compared to the corresponding quarter last year. At comparable exchange rates and adjusted for acqusitions[1)] sales increased by 8.1 percent. · Operating profit increased by 42.5 percent to 64.3 MSEK (45.1). · Result after tax increased by 51.3 percent to 66.6 MSEK (44.0). · Earnings per share increased to 1.02 SEK (0.68) before and after dilution. · The cash flow from operating activities increased to 80.0 MSEK (50.7). · Net debt[1)]

Very strong increase of sales during the third quarter

Q3 · Net sales reached SEK 19.5 (13.2) million. · Result after tax came in at SEK -7.7 (-9.6) million. · Earnings per share, basic and diluted, were SEK-0.05 (-0.11). · Cash and cash equivalents were SEK 30.7 (9.5) million. Significant events in Q3 · Enzymatica launched ColdZyme® Strawberry and broadened use to include soothe sore throat and alleviate common cold symptoms. · Sales surged on the Swedish market and ColdZyme continued to capture market share in terms of both value and volume. Sales on the Danish and Spanish markets also showed strong growth. ·

Interim report January - September 2019

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value rose to SEK 127 per share, compared with SEK 100 per share at the start of the year. This is an increase of 29.9 per cent, adjusted for dividends. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 23.0 per cent. The net asset value was SEK 133 per share at 4 November.(1) · The total return on the Latour share was 17.9 per cent during the period measured against the SIXRX, which rose 23.0 per cent. INDUSTRIAL OPERATIONS The third quarter · The industrial operations' order intake

Bioservo Technologies AB Interim report 1 January to 30 September 2019

Third quarter in figures · Net sales SEK 1.7 M (1.0) · EBITDA of SEK -4.6 M (-5.8) · EBIT of SEK -5.5 M (-6.7) · Earnings for the period was SEK -5.5 M (-6.7) · Earnings per share before and after dilution amounted to SEK -0.61 (-0.75) · At 30 September, cash and cash equivalents were SEK 9.4 M (32.1)   First nine months in figures · Net sales SEK 6.9 M (4.0) · EBITDA of SEK -13.8 M (-14.9) · EBIT of SEK -16.6 M (-17,2) · Earnings for the period was SEK -16.6 M (-17.2) · Earnings per share before and after dilution amounted to SEK -1.86 (-1.93) ·

Kallelse till extra bolagsstämma i TargetEveryOne AB (publ)

Aktieägarna i TargetEveryone AB (publ), org. nr. 556526-6748 (”Bolaget”), kallas härmed till extra bolagsstämma den 20 november 2019 klockan 11 på Kungsgatan 60, 1 tr. i Stockholm. Aktieägare som vill delta i stämman ska dels vara införda i den av Euroclear Sweden AB förda aktieboken den 14 november 2019, dels anmäla sitt deltagande till Bolaget senast den 14 november 2019, per post till adress TargetEveryOne AB, Kungsgatan 60, 1 tr, 112 22 Stockholm, eller per e-post (e-post_info@targeteveryone.com) info@targeteveryone.com. Vid anmälan anges namn, adress, telefonnummer, person- eller

Termination of project regarding ROR-gamma

In December 2011, Karo Pharma Aktiebolag (”Karo Pharma”) entered into a research collaboration and license agreement with Pfizer, with the purpose of discovering and developing substances that hamper the activity in the nuclear hormone receptor ROR-gamma, for treatment of autoimmune diseases. After completion of the initial research collaboration, Pfizer has conducted the development work in-house, in accordance with the terms of the agreement. Pfizer has informed Karo Pharma about its decision to terminate the specific development project, PF-06763809. As a result, Karo Pharma will not

Klaria acquires Uppsalagruppen and becomes the owner of the patent that protects Klaria’s technology platform

Klaria Pharma Holding AB (publ) (“Klaria”) today acquires Uppsalagruppen Medical AB (“Uppsalagruppen”) and the patent that protects Klaria’s drug delivery technology.  To date, Klaria has had a license from Uppsalagruppen to this patent for specific molecules.  With this acquisition, Klaria will now own the patent and have full freedom to develop novel drug candidates in the future.The transaction is structured as a share transfer agreement between the owners of Klaria and Uppsalagruppen, whereby all shares in Uppsalagruppen are acquired by Klaria. As consideration, Klaria has agreed to pay

Aspire Global’s Interim Report for the Third Quarter 2019 – Two Years of Sustained Growth

Third Quarter 2019 (JUL-SEP) · Revenues increased by 16.2% to €33.2 million (28.6) · B2B revenues increased by 37.9% to €21.0 million (15.2), constituting 63.0% of total revenues · EBITDA decreased by 16.0% to €5.2 million (6.2) · EBITDA for B2B increased by 15.0% to €4.3 million (3.7), constituting 82.0% of total EBITDA · EBITDA margin amounted to 15.7% (21.6%) · EBIT decreased to €4.3 million (5.7) · Earnings after tax decreased to €4.4 million (5.3) · Earnings per share after tax decreased to €0.09 (0.11) · First time depositors (FTDs) increased by 24.0% to

Starbreeze AB (publ) interim Q3 2019 report

Third quarter 2019 · Net sales amounted to SEK 21.1 million (33.9). PAYDAY accounted for SEK 17.5 million (20.9). · EBITDA amounted to SEK -10.9 million (-37.9). · Depreciation, amortization and impairments totalled SEK 94.9 million (49.5). · Costs related to the reconstruction amounted to SEK 4.5 million for the quarter.  · The loss before tax was SEK -68.4 million (-102.3). · Basic and diluted earnings per share were SEK -0.21 (-0.26). · The Stockholm District Court ruled that the reconstruction of Starbreeze was permitted to continue through 3 December 2019.

ÅF Pöyry acquires Cervino Consulting AB

The acquisition will make ÅF Pöyry a more complete supplier of engineering and design solutions in all areas of defenceCervino was founded in 2013 and offers consulting services to the defence, aviation and transport industries. The company works with operational and maintenance-related systems and offers project management, process innovation and support for transitioning to digital technology. ÅF Pöyry is today one of Sweden’s leading service providers to the Swedish defence sector. This acquisition will make ÅF Pöyry an even more complete supplier in all areas of defence and will

Ahlstrom-Munksjö and Metsä Fibre makes cross-audits in Germany

AHLSTROM-MUNKSJÖ, PRESS RELEASE, NOVEMBER 5, 2019 at 9:00 A.M. EETAhlstrom-Munksjö and Metsä Fibre continue collaboration in safety. A pilot program started with cross-audits in both companies’ production facilities in Finland in late 2018. After encouraging results the companies decided to expand auditing collaboration outside Finland. In the autumn 2019 Metsä Fibre safety professionals audited Ahlstrom-Munksjö plants in Dettingen and Unterkochen in Germany.Program tagline ‘Safety has no boundaries’ captures the essential idea of safety collaboration between the two companies. In

Neste’s new IMO2020-compliant low-sulphur marine fuel available in Germany

Neste Corporation, Press Release, 5 November 2019 at 9 a.m. (EET) Neste and the German BMT Bunker und Mineralöltransport GmbH have signed a partner agreement concerning distribution and sales of Neste MarineTM 0.5 . This new marine fuel, containing maximum 0.5% sulphur, has been available in Bremerhaven, Germany, since the beginning of November 2019.   BMT is a bunkering services company with a long experience in the sales of marine fuels. The company is well-known especially in the North Sea coast in

IAR Systems delivers development from device to cloud through integration with Amazon Web Services

Stockholm, Sweden—November 5, 2019— IAR Systems®, the future-proof supplier of software tools and services for embedded development, launches a new edition of IAR Embedded Workbench® for Arm® that provides integration with Amazon Web Services (AWS). “Embedded software development is extending into the cloud and developers need to be in control of application behavior through all execution stages to be able to optimize and debug their code in an efficient way,” says Anders Holmberg, Chief Strategy Officer, IAR Systems. “We provide developers with easy access to high-performance, pre-

IAR Systems delivers development from device to cloud through integration with Amazon Web Services

IAR Embedded Workbench for Arm now enables debugging all the way up to the cloudUppsala, Sweden—November 5, 2019—IAR Systems®, the future-proof supplier of software tools and services for embedded development, launches a new edition of IAR Embedded Workbench® for Arm® that provides integration with Amazon Web Services (AWS). IAR Embedded Workbench for Arm, AWS edition, provides developers with the possibility to log in to an AWS account from within the C/C++ development toolchain IDE. During debugging, they are able to access the TCP/IP interface, see the status of MQTT packages and

Boozt AB’s (publ) Nomination Committee appointed

The Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting and has the following composition: · Claus Wiinblad (representing ATP), Chairman of the Nomination Committee · Daniel Ahlstrand (representing Verdane Capital VII K/S) · Johannes Wingborg (representing Länsförsäkringar) · Henrik Theilbjørn, Chairman of the Board of Boozt AB (publ) The Chairman of the Board shall also summon the first meeting of the Nomination Committee. The Nomination Committee submits proposals to the AGM regarding the composition of the Board,

There are no items matching the current filter
There are no more items matching the current filter
Back to top